Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Tumor protein p53 (TP53) is the most frequently mutated gene in cancer1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease3,4, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies6,7,8 and dismal outcomes9....
Main Authors: | Bernard, E, Nannya, Y, Hasserjian, RP, Boultwood, J, Pellagatti, A |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
Springer Nature
2020
|
Registos relacionados
-
NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
Por: Fidler, C, et al.
Publicado em: (2004) -
TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Por: Ramy Rahmé, et al.
Publicado em: (2023-04-01) -
Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation
Por: Čolović Nataša, et al.
Publicado em: (2023-01-01) -
Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes
Por: Lijuan Zhang, et al.
Publicado em: (2023-12-01) -
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Por: Haase, D, et al.
Publicado em: (2019)